Director Blake Borgeson of Recursion Pharmaceuticals, Inc. filed a Form 4 on November 4, 2026, disclosing the sale of 40,000 shares of Class A Common Stock on November 3, 2026, under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Shares sold: 40,000 shares of Class A Common Stock disposed of on November 3, 2026
  • Weighted average price: $3.88 per share, with individual trades ranging from $3.84 to $4.00
  • Remaining holdings: 6,068,287 shares of Class A Common Stock beneficially owned directly following the transaction
  • 10b5-1 plan: The sale was made pursuant to a Rule 10b5-1 trading plan adopted by Borgeson on August 31, 2025
  • Reporting person role: Blake Borgeson is identified as a Director of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Borgeson's November 3 Share Disposal Under 10b5-1 Plan

According to the filing, director Blake Borgeson disposed of 40,000 shares of Recursion Pharmaceuticals Class A Common Stock on November 3, 2026. The transaction was executed in multiple trades at prices ranging from $3.84 to $4.00, with a weighted average sale price of $3.88. The filing notes that Borgeson "undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."

The filing discloses that the sale was conducted pursuant to a Rule 10b5-1 trading plan that Borgeson adopted on August 31, 2025. The Form 4 box indicating a transaction "made pursuant to a contract, instruction or written plan" satisfying Rule 10b5-1(c) affirmative defense conditions was checked. The filing was signed by Kyle Nelson as attorney-in-fact on November 3, 2026.

Following the reported transaction, Borgeson's direct beneficial ownership of Recursion Pharmaceuticals Class A Common Stock stands at 6,068,287 shares, as reported in the filing. No derivative securities transactions were reported in Table II of the form.

What Was Disclosed

Blake Borgeson, a director at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), disclosed the sale of 40,000 Class A Common Stock shares at a weighted average price of $3.88 on November 3, 2026, under a 10b5-1 plan adopted August 31, 2025, leaving him with 6,068,287 shares.